Company Description
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders.
Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials.
In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders.
The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
| Country | United States |
| Founded | 2017 |
| IPO Date | Mar 26, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 110 |
| CEO | Kevin Koch |
Contact Details
Address: 1715 38th Street Boulder, Colorado 80301 United States | |
| Phone | 720 262 7002 |
| Website | edgewisetx.com |
Stock Details
| Ticker Symbol | EWTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001710072 |
| CUSIP Number | 28036F105 |
| ISIN Number | US28036F1057 |
| Employer ID | 82-1725586 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Kevin Koch Ph.D. | President, Chief Executive Officer and Director |
| Dr. Behrad Derakhshan Ph.D. | Chief Operating Officer |
| Dr. Joanne M. Donovan M.D., Ph.D. | Chief Medical Officer |
| Dr. Alan J. Russell Ph.D. | Co-Founder, Chief Scientific Officer and Director |
| Michael P. Nofi | Chief Financial Officer |
| John R. Moore J.D. | General Counsel |
| Dr. Robert Blaustein M.D., Ph.D. | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 20, 2025 | 8-K | Current Report |
| Nov 17, 2025 | 144 | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 12, 2025 | 144 | Filing |
| Nov 10, 2025 | 8-K | Current Report |
| Nov 6, 2025 | 10-Q | Quarterly Report |
| Nov 6, 2025 | 8-K | Current Report |
| Aug 26, 2025 | 144 | Filing |
| Aug 14, 2025 | SCHEDULE 13G/A | Filing |